Q-Vant Collaborates with Tulane University to Develop a Promising New Oral Vaccine Adjuvant News Q-Vant Collaborates with Tulane University to Develop a Promising New Oral Vaccine Adjuvant
Q-VANT and SPI Pharma Offering Broader Access to Sustainable and Scalable Pharma-grade Saponin Adjuvants Press Q-VANT and SPI Pharma Offering Broader Access to Sustainable and Scalable Pharma-grade Saponin Adjuvants
Q-VANT and In Vitro Plant-tech Sign Agreement for the Development and Supply of Quillaja saponaria Plant Cell Culture Biomass News Q-VANT and In Vitro Plant-tech Sign Agreement for the Development and Supply of Quillaja saponaria Plant Cell Culture Biomass
Q-VANT Biosciences Launches to Solve the Pharmaceutical Industry Problem of Limited Quillaja Saponin Adjuvants for Life-Saving Vaccines Press Q-VANT Biosciences Launches to Solve the Pharmaceutical Industry Problem of Limited Quillaja Saponin Adjuvants for Life-Saving Vaccines
Q-VANT’s Chief Scientific Officer Shares Insights Gleaned from His Decades in Vaccine Development News Q-VANT’s Chief Scientific Officer Shares Insights Gleaned from His Decades in Vaccine Development
Quillaja saponaria, the Chilean Tree Under Increasing Pressure News Quillaja saponaria, the Chilean Tree Under Increasing Pressure
